Rekord LOINC: 100861-4
Tylko wersja angielska TRIAL
Szczegóły rekordu LOINC
Informacje podstawowe
| Kod LOINC: |
100861-4
FHIR
|
| Long Common Name: | Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide |
| Short Name: | CD4+154/CD4 p COVID NuclCap |
| Status: | TRIAL |
| Class Type: | 1 |
Fully Specified Name (FSN)
EN
Oryginalna wersja angielska
Cells.CD4+CD154+/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide
:
NFr
:
Pt
:
Bld
:
Qn
:
-
Klasyfikacja
| Class: |
ENMICRO
|
| Consumer Name: | - |
| Order/Observation: | Both |
| Panel Type: | - |
Informacje dodatkowe
| Units Required: | N |
| Example Units: | % |
| UCUM Units: | % |
| Version Last Changed: | 2.73 |
Powiązane nazwy
Blood; CD4 Cells; CD4+154 cells; CD40 ligand; CD40L; Cell; Cellularity; gp39; Helper T cells; ID; II; Inducer T cells; Infectious Disease; InfectiousDisease; L3T4; Leu3; Leu-3; Microbiology; Number Fraction; p COVID NuclCap; Pept; Percent; PH; Point in time; Public Health; PublicHealth; QNT; Quan; Quant; Quantitative; Random; Severe Acute Respiratory Syndrome; Stim; T4; T-4; T-BAM; TRAP; Tumor necrosis factor Related Activation Protein; W3/25; WB; Whole blood; X-linked hyper IgM